FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2014729315> ?p ?o ?g. }

• W2014729315 endingPage "165" @default.
• W2014729315 startingPage "161" @default.
• W2014729315 abstract "The demonstration in animals that recombinant tissue-type plasminogen activator produces prolonged thrombolysis after its clearance from the circulation has prompted a few pilot studies of bolus administration in patients. Alteplase (bolus dose of 70 mg) resulted in the highest recanalization rate in our previous pilot study comparing bolus doses of 50, 60 and 70 mg of alteplase in patients with acute myocardial infarction. The aim of the present trial was to assess the efficacy and safety of the same bolus dose in a larger number of patients. A further objective was to study the angiographic reocclusion rate at 12 to 24 hours in patients who had a recanalized infarct-related coronary artery at 90 minutes and were randomized at that time to a bolus dose or an infusion for 3 hours of 30 mg of alteplase. Sixty patients with acute myocardial infarction and angiographically documented total occlusion of the infarct-related coronary artery before thrombolysis were treated within 5 hours of onset of symptoms with an intravenous 70-mg bolus dose of alteplase (or 80 mg if body weight was ≥90 kg). Each patient received 5,000 IU of heparin intraarterially and 100 mg of aspirin by mouth before administration of alteplase. Coronary angiography was repeated 60 and 90 minutes after alteplase administration. The recanalization rate of the infarct-related coronary artery was 55% (95% confidence interval, 43 to 66%) at 60 minutes and 48% (95% confidence interval, 37 to 60%) at 90 minutes. Pretreatment levels of lipoprotein (a) were not significantly related to recanalization. Twenty-three patients, who had a patent infarct-related coronary artery during 90-minute angiography and did not require immediate coronary intervention, were then given an additional 30 mg of alteplase, randomly either as an intravenous bolus dose or as an intravenous infusion over 3 hours. Heparin treatment was continued in randomized patients with an intravenous infusion of 1,000 IU of heparin per hour between the time of the 90-minute angiography and the control angiography at 12 to 24 hours. At this final angiography, reocclusion of the infarct-related coronary artery was seen in 1 patient randomized to alteplase infusion (reocclusion rate 4%). Plasma fibrinogen (mean ± standard deviation) before and 90 and 270 minutes after a bolus dose of alteplase was 2.74 ± 0.56, 1.59 ± 0.85 and 1.64 ± 0.84 g/liter, respectively, when assessed as total clottable protein, and 2.85 ± 1.04, 0.77 ± 0.73 and 1.01 ± 1.06 g/liter, respectively, when measured by a clotting rate assay. Only minor bleeding was observed in 65% (95% confidence interval, 53 to 75%) of patients and occurred primarily at puncture sites. In 6 patients a transient decrease of systolic blood pressure ≤90 mm Hg was observed during the first 90 minutes. There were no deaths within 14 days. In considering the recanalization rates obtained in this study, a 70-mg bolus injection of alteplase does not appear to be an optimally effective dosage regimen in the treatment of acute myocardial infarction." @default.
• W2014729315 created "2016-06-24" @default.
• W2014729315 creator A5001446916 @default.
• W2014729315 creator A5002753016 @default.
• W2014729315 creator A5010614061 @default.
• W2014729315 creator A5019532695 @default.
• W2014729315 creator A5070495078 @default.
• W2014729315 creator A5076111090 @default.
• W2014729315 date "1991-07-01" @default.
• W2014729315 modified "2023-09-24" @default.
• W2014729315 title "Coronary recanalization rate after intravenous bolus of alteplase in acute myocardial infarction" @default.
• W2014729315 cites W1970055375 @default.
• W2014729315 cites W1971481361 @default.
• W2014729315 cites W1973948925 @default.
• W2014729315 cites W1978039741 @default.
• W2014729315 cites W1983126671 @default.
• W2014729315 cites W1989335326 @default.
• W2014729315 cites W1994313737 @default.
• W2014729315 cites W2003610429 @default.
• W2014729315 cites W2015830963 @default.
• W2014729315 cites W2040675937 @default.
• W2014729315 cites W2041176958 @default.
• W2014729315 cites W2049490014 @default.
• W2014729315 cites W2050962788 @default.
• W2014729315 cites W2055482803 @default.
• W2014729315 cites W2060983762 @default.
• W2014729315 cites W2078635736 @default.
• W2014729315 cites W2083147570 @default.
• W2014729315 cites W2085773413 @default.
• W2014729315 cites W2093923223 @default.
• W2014729315 cites W2114124608 @default.
• W2014729315 cites W2129127648 @default.
• W2014729315 cites W2146083057 @default.
• W2014729315 cites W2402345560 @default.
• W2014729315 cites W2441039248 @default.
• W2014729315 cites W4235632139 @default.
• W2014729315 doi "https://doi.org/10.1016/0002-9149(91)90737-6" @default.
• W2014729315 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1829574" @default.
• W2014729315 hasPublicationYear "1991" @default.
• W2014729315 type Work @default.
• W2014729315 sameAs 2014729315 @default.
• W2014729315 citedByCount "22" @default.
• W2014729315 countsByYear W20147293152016 @default.
• W2014729315 countsByYear W20147293152017 @default.
• W2014729315 countsByYear W20147293152022 @default.
• W2014729315 countsByYear W20147293152023 @default.
• W2014729315 crossrefType "journal-article" @default.
• W2014729315 hasAuthorship W2014729315A5001446916 @default.
• W2014729315 hasAuthorship W2014729315A5002753016 @default.
• W2014729315 hasAuthorship W2014729315A5010614061 @default.
• W2014729315 hasAuthorship W2014729315A5019532695 @default.
• W2014729315 hasAuthorship W2014729315A5070495078 @default.
• W2014729315 hasAuthorship W2014729315A5076111090 @default.
• W2014729315 hasConcept C126322002 @default.
• W2014729315 hasConcept C164705383 @default.
• W2014729315 hasConcept C2776820930 @default.
• W2014729315 hasConcept C2777628954 @default.
• W2014729315 hasConcept C2779581417 @default.
• W2014729315 hasConcept C42219234 @default.
• W2014729315 hasConcept C43376680 @default.
• W2014729315 hasConcept C500558357 @default.
• W2014729315 hasConcept C71924100 @default.
• W2014729315 hasConceptScore W2014729315C126322002 @default.
• W2014729315 hasConceptScore W2014729315C164705383 @default.
• W2014729315 hasConceptScore W2014729315C2776820930 @default.
• W2014729315 hasConceptScore W2014729315C2777628954 @default.
• W2014729315 hasConceptScore W2014729315C2779581417 @default.
• W2014729315 hasConceptScore W2014729315C42219234 @default.
• W2014729315 hasConceptScore W2014729315C43376680 @default.
• W2014729315 hasConceptScore W2014729315C500558357 @default.
• W2014729315 hasConceptScore W2014729315C71924100 @default.
• W2014729315 hasIssue "2" @default.
• W2014729315 hasLocation W20147293151 @default.
• W2014729315 hasLocation W20147293152 @default.
• W2014729315 hasOpenAccess W2014729315 @default.
• W2014729315 hasPrimaryLocation W20147293151 @default.
• W2014729315 hasRelatedWork W130564172 @default.
• W2014729315 hasRelatedWork W136901553 @default.
• W2014729315 hasRelatedWork W2021426128 @default.
• W2014729315 hasRelatedWork W2075711202 @default.
• W2014729315 hasRelatedWork W2086461862 @default.
• W2014729315 hasRelatedWork W2118678945 @default.
• W2014729315 hasRelatedWork W2358124809 @default.
• W2014729315 hasRelatedWork W2414559986 @default.
• W2014729315 hasRelatedWork W2528401602 @default.
• W2014729315 hasRelatedWork W2885168853 @default.
• W2014729315 hasVolume "68" @default.
• W2014729315 isParatext "false" @default.
• W2014729315 isRetracted "false" @default.
• W2014729315 magId "2014729315" @default.
• W2014729315 workType "article" @default.